Lauren Pinter-Brown

picture of Lauren  Pinter-Brown

Professor, Department of Medicine, Division of Hematology/Oncology


M.D., University of California, Los Angeles, 1980


Residency, Harbor-UCLA Medical Center, 1983


Fellowship, University of California, Los Angeles, 1986

Phone: (714) 456-5153
Fax: (714) 456-2242
Email: lpinterb@uci.edu

University of California, Irvine
101 City Drive South, Bldg 56, Rm 232
Mail Code: 4061
Orange, CA 92868
Research Interests
optimizing treatment options for patients with lymphoma especially cutaneous and T-cell lymphomas
URL
Publications
Pinter-Brown LC. Diagnosis and management of Cutaneous B-cell lymphoma. Dermatol Clin. 2015; 33(4): 835-40
 
Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Ann Oncol. 2015; 26(4): 774-9.
 
Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman M, Ballerini R, Liu L, Kim YH. Phase1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015; 125(12): 1883-9.
 
Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, Carlson G, Lechner MG, Epstein AL. Anaplastic large cell lymphoma occurrig in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015; 135(3): 695-705.
 
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenword M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown LC, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7(1): 11.
 
Loh, JC, Cassarino DS, Grody WW, Chiu MW, Pinter-Brown LC. A case of mycosis fungoides transmitted from donor to recipient, and review of the literature of T-cell malignancies after transplantation. Clin Lymphoma Myeloma Leuk. 2014; 14(4): e137-40.
 
Foss F, Horwitz SM, Coiffier B, Bartlett N, Popplewell L, Pro B, Pinter-Brown LC, Shustov A, Furman RR, Haioun C, Koutsoukos T, O’Connor OA. Pralatrexate is an effective treatment fro relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43.
 
Magorien J, Hillman JD, Pinter-Brown LC, Said J, Chiu MW: Acral lymphomatoid papulosis associated with poikilodermatous mycosis fungoides. Dermatology Online J. 2013 Feb 15; 19(2): 1.
 
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchman P, Morschhauser F, Wilheim M, Pinter-Brown L, Padmanabhan S, Shustov A, Nicols J, Carroll S, Baiser J, Baiser B, Horowitz S: Results from a pivotal, open-label phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after poor systemic therapy. J Clin Oncol, 30(6):631-6, 2012.
 
Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kazimierz K, Link BK, Pinter-Brown L, Radford J, Heilmann A, Gallop-Evans E, Direnzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A: Ofatumumab Monotherapy in Rituximab-Refractory Follicular Lymphoma: Results from a Multicenter Study. Blood, Mar 2, 2012
 
Andorsky DJ, Cohen M, Naeim A, Pinter-Brown L: Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant, 46(9):1219-25, 2011.
 
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol, 29(9):1182-9, 2011.
 
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC; International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer: Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer. J Clin Oncol, 29(81):2598-607, 2011.
 
Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter- Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST: Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma, 52(8):1474-80, 2011.
 
Pinter-Brown LC: Discussion: A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. Plast Reconstr Surg, 128(3):122e-123e, 2011.
 
Alamdari HS, Pinter-Brown L, Cassarino DS, Chiu M: Severe cutaneous interface drug eruption associated with bendamustine. Dermatol Online J, 16(7):1, 2010.
 
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH: Phase I trial of a Toll-like receptor 9 (TLR 9) agonist, PF-3512676 (CpG 7909), in Patients with treatment-refractory cutaneous T-cell lymphoma. J Am Acad Dermatol, 63(6):975-83, 2010.
 
Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfield C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Carcchio P, Duvic M: Sézary syndrome: Immunogpathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC), J Am Acad Dermatol, 64(2):352-404, 2011.
 
Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH: A Phase II Study of SGN-30 (anti-CD30 mAb) in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Diseases. Clin Cancer Res, 15(19):6217-24, 2009.
 
Forero-Torres A, Leonard J, Younes A, Rosenblatt J, Brice B, Bartlett N, Bosly A, Pinter-Brown L, Kennedy D, Sievers E, Gopal AJ: A Phase II Study of SGN-30 (anti-CD30 mAB) in Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma, Br J Haematol, 146(2):171-9, 2009.
 
Ralli M, Goldman J, Lee E, Pinter-Brown L, Glasgow B, Sarraf D: Intraocular Involvement of Mycosis Fungoides, Archives of Ophthalmology, 127(3):343-5, 2009.
 
Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RG, Sherman S I, Duvic M: Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab, 91(6):2205-8, 2006.
 
Emmanoulides C, Colovos D, Pinter-Brown L, Hernandez L, Schiller G, Territo M, Rosen P: Pilot Study of Fixed-Infusion Rate Gemcitabine with Cisplatin and Dexamethasone in Patients with Relapsed or Refractory Lymphoma. Clinical Lymphoma, 5(1):45-49, 2004.
 
Han K, Haley J, Carlson K, Pinter-Brown L, Soriano T: Regression of cutaneous Intravascular lymphoma with Rituximab. Cutis, 72(2): 137-40, 2003.
 
Roberts AA, Amano M, Felten, C, Galvan M, Solor G, Pinter-Brown L, Dobbeling U, Burg G, Said J, Baum LG: Galectin-1-mediated apoptosis in Mycosis Fungoides: the roles of CD7 and cell surface glycosylation. Modern Pathology, 16(6):543-51, 2003.
 
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J: Pivotal Phase III Trial of Two Dose Levels of DAB389IL-2 (ONTAK7) for the Treatment of Cutaneous T-Cell Lymphoma. J Clin Oncology, 19(2):376-88, 2001.
 
Ellison DJ, Hu E, Zavian D, Pinter-Brown L, Pattengale PK: Immunogenetic analysis of bone marrow aspiration in patients with non-Hodgkin’s lymphoma. Am J Hem, 33(3):160-166, 1990.
 
Pinto PC, Hu E, Bernstein-Singer M, Pinter-Brown L, Gouindarajan S: Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer, 65(4):878-884, 1990.
 
Nguyen D, Brynes RK, Macaulay L, Kaplan B, Pinter-Brown LC: Acute myeloid leukemia, FAB M-1 microgranular variant: A multiparameter study. Hematology Pathology, 3(1):11-22, 1989.
 
Hu E, Hufford S, Lukes R, Bernstein-Singer M, Sobels G, Gill P, Pinter-Brown L, Rarick M, Rosen P, Brynes R, Nathwani B, Feinstein D, Levine A: Third world Hodgkin's Disease at Los Angeles County-University of Southern California Medical Center. J Clin Oncology, 6(8):1285-1292, 1988.
 
Chandrasoma P, Shibata D, Radin R, Pinter-Brown L, Koss M: Malignant peripheral nerve sheath tumor arising in an adrenal ganglioneuroma in an adult male homosexual. Cancer, 57(10):2022-2025, 1986.
Professional Societies
Alpha Omega Alpha
American Society of Clinical Oncology
American Society of Hematology
American College of Physicians
Southern California Academy of Clinical Oncology
International Society for Cutaneous Lymphoma
Los Angeles Academy of Medicine
United States Cutaneous Lymphoma Consortium
Other Experience
Clinical Professor
University of California, Los Angeles

Assistant Professor
University of Southern California

Independent Investigator
National Cancer Institute

Acting Clinical Director
LAC/USC Medical Center Sickle Cell Center

Clinical Director
LAC/USC Hematologic Neoplasia Service

Co-Director
Photophereis Program, University of Southern California

Co-Coordinator
Hematology/Oncology Clinics, Olive View-UCLA Medical Center

Associate Chief
Hematology/Oncology, Olive View-UCLA Medical Center

Director
UCLA Lymphoma Program

Board of Directors
Cutaneous Lymphoma Foundation

Last updated
04/25/2016